top of page

Original on Transparent.png

Anti-obesity medications aggregator

Phase 1 data in obese, non-diabetic patients

For phase 2 click here

References (each reference is linked to the publication/ press release):

1. Tirzepatide data from: Coskun T et al . Mol Metab. 2018 Dec;18:3-14;

3. MariTide data from: Véniant MM et al. Nat Metab. 2024 Feb;6(2):290-303.

2. Orforglipron data from: Pratt E, Diabetes Obes Metab. 2023;25(9):2634‐2641;

6. CT-388 phase1b data from: ROCHE's Virtual Investor Event at EASD – presentation;

4. VK2735 data from VIKING Therapeutics - Corporate presentation;

5. CT-388 phase 1 data from: CARMOT Therapeutics website;

7. CT 996 phase 1 data from: ROCHE's Virtual Investor Event at EASD – presentation;

8. TERN-601 phase 1 data from: TERNS Pharmaceuticals – topline results;

9. Amycretin phase 1 data from: EASD 2024 OP 13 GLP-1-based polypharmacology: we are not done yet!

bottom of page